Integral Health Asset Management’s Cytokinetics CYTK Stock Holding History

Integral Health Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,000,000	Closed	-$65.9M	–	97
2026 Q1	$65.9M	Buy	1,000,000 +500,000	+100%	+$31.8M	3.15%	5
2025 Q4	$31.8M	Sell	500,000 -250,000	-33%	-$15.6M	1.58%	17
2025 Q3	$41.2M	Buy	750,000 +250,000	+50%	+$10.3M	2.79%	6
2025 Q2	$16.5M	Buy	+500,000	New	+$17.4M	1.51%	25
2024 Q1	–	Sell	-400,000	Closed	-$33.4M	–	85
2023 Q4	$33.4M	Buy	+400,000	New	+$14.5M	4.55%	1
2023 Q1	–	Sell	-400,000	Closed	-$18.3M	–	75
2022 Q4	$18.3M	Sell	400,000 -56,300	-12%	-$2.42M	3.85%	1
2022 Q3	$22.1M	Buy	+456,300	New	+$22M	4.29%	2
2020 Q4	–	Sell	-200,000	Closed	-$4.33M	–	64
2020 Q3	$4.33M	Buy	+200,000	New	+$4.68M	1.32%	25

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Integral Health Asset Management's CYTK Position: Q2 2026 in Review

Integral Health Asset Management held its Cytokinetics (CYTK) position steady in Q2 2026 at 1,600,000 shares worth $136M. The position accounts for 5.38% of the portfolio, ranked #3.

Integral Health Asset Management first reported a position in CYTK in Q1 2020 and has held it in 26 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Integral Health Asset Management held 1,600,000 shares of Cytokinetics worth $136M as of Q2 2026.
Integral Health Asset Management left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up 5.38% of Integral Health Asset Management's portfolio in Q2 2026, its #3 holding.
Integral Health Asset Management first reported a position in Cytokinetics in Q1 2020 and has held it in 26 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.